title: Accumulation of sphingolipids in SAP-precursor (prosaposin)-deficient fibroblasts occurs as intralysosomal membrane structures and can be completely reversed by treatment with human SAP-precursor.
abstract: The degradation of glycosphingolipids takes place in lysosomes by action of specific exohydrolases, with the assistance of sphingolipid activator proteins (SAPs). Four of the SAPs, SAP-A to -D (also called saposins A to D), are synthesized from a single protein, the SAP-precursor (prosaposin). Deficiency in this precursor protein, a rare inherited disease in humans, results in the storage of sphingolipids with short oligosaccharide head groups within the patients' tissues, and electron microscopy revealed the accumulation of large multivesicular storage organelles. In this study we analyze the multivesicular storage organelles in cultivated fibroblasts from these patients. The results support our hypothesis that endocytosis of plasma membrane-derived lipids occurs via small intraendosomal and intralysosomal vesicles and membrane structures that are then digested within the lysosomes (Sandhoff, K., T. Kolter, Trends in Cell Biol. 6, 98-103 (1996). First, we show that the storage compartment consists of late endosomes and lysosomes by immunogold labeling for marker proteins of these organelles. The transport of endocytosed bovine serum albumin-colloidal gold or cationized ferritin into the compartment occurs with the timing expected for transport to late endocytic organelles. Second, complementation of the medium of the SAP-precursor-deficient fibroblasts with only nanomolar concentrations of purified SAP-precursor nearly completely reversed the aberrant accumulation of multivesicular structures, thereby abolishing most of the intralysosomal membrane structures. Analysis of the sphingolipid pattern of the cells after metabolic labeling with [14C]serine reveals that the cells' ability to degrade glycosphingolipids is completely restored by feeding of SAP-precursor at the same concentrations. This is the first demonstration in vivo that endocytosed SAP-precursor is processed into functional active SAPs A,- B,- C, and D and that the degradation of the vesicular structures within the lysosomes depends on the presence of the SAPs. Moreover, these studies suggest that a therapy program based on feeding purified SAP-precursor may be valuable in treating the entire family of diseases which result from the loss of one or more of the SAPs.
authors.affiliation: European Molecular Biology Laboratory, Heidelberg/Germany.
authors.forename: J K
authors.initials: JK
authors.lastname: Burkhardt
authors.forename: S
authors.initials: S
authors.lastname: Hüttler
authors.forename: A
authors.initials: A
authors.lastname: Klein
authors.forename: W
authors.initials: W
authors.lastname: Möbius
authors.forename: A
authors.initials: A
authors.lastname: Habermann
authors.forename: G
authors.initials: G
authors.lastname: Griffiths
authors.forename: K
authors.initials: K
authors.lastname: Sandhoff
mesh_terms: D011992:Endosomes / Q000187:drug effects / Q000378:metabolism / Q000648:ultrastructure; D005347:Fibroblasts / Q000187:drug effects / Q000378:metabolism / Q000648:ultrastructure; D006023:Glycoproteins / Q000172:deficiency / Q000378:metabolism / Q000494:pharmacology*; D006028:Glycosphingolipids / Q000378:metabolism*; D006801:Humans; D002479:Inclusion Bodies / Q000187:drug effects / Q000378:metabolism / Q000648:ultrastructure; D007223:Infant; D007425:Intracellular Membranes / Q000187:drug effects / Q000378:metabolism* / Q000648:ultrastructure; D016464:Lysosomal Storage Diseases / Q000188:drug therapy / Q000378:metabolism / Q000473:pathology; D008247:Lysosomes / Q000187:drug effects / Q000378:metabolism* / Q000648:ultrastructure; D010641:Phenotype; D011498:Protein Precursors / Q000172:deficiency / Q000378:metabolism / Q000494:pharmacology*; D049231:Saposins
chemical_list: D006023:Glycoproteins; D006028:Glycosphingolipids; C483345:PSAP protein, human; D011498:Protein Precursors; D049231:Saposins